Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02775045 · ClinicalTrials.gov registry record
Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis
A clinical trial, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- 28
- Enrollment target
NCT02775045: Completed study, sponsored by University of Wisconsin, Madison.
NCT02775045 is a clinical trial that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02775045 has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to improve the overall management of patients with Eosinophil Esophagitis. Currently, the best way to monitor Eosinophil Esophagitis is repeating the endoscopy procedure. The investigators plan to identify a biomarker in the blood (a measurable substance) that tracks with disease activity and will reduce the need for follow-up endoscopies.
Interventions
- OTHER Observation Period
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-08-30 |
| Est. Completion | 2018-12-13 |
What the finished NCT02775045 record still lists
NCT02775045 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Observation Period is the first listed.
NCT02775045 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02775045 about?
NCT02775045 is a clinical study titled "Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis". The purpose of this study is to improve the overall management of patients with Eosinophil Esophagitis. Currently, the best way to monitor Eosinophil Esophagitis is repeating the endoscopy procedure. The investigators plan to identify a biomarker in the blood (a measurable substance) that tracks wit...
What is the current status of trial NCT02775045?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2016-08-30. Estimated completion is 2018-12-13.
What interventions are being tested in trial NCT02775045?
The interventions under investigation include: Observation Period (OTHER).
Who is sponsoring clinical trial NCT02775045?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI